Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 2021

View Archived Issues

Anti-PD-L1 IGM-7354 shows promise for cancer immunotherapy

Rat model for PD using AAV-induced overexpression of E46K-like alphaSYN mutants

Antibody-drug conjugate SGN-B7H4V shows promise in preclinical models of cancer

SGN-PDL1V, a PD-L1-directed ADC with activity in multiple tumor xenograft models

Hangzhou Innogate Pharma divulges SYK and JAK2 kinase inhibitors

Betta Pharmaceuticals patents new compounds for cancer

Beijing Tide Pharmaceutical identifies GTPase KRAS inhibitors

Chinese researchers synthesize new phosphodiesterase PDE4 inhibitors

Biopolar Hongye (Nantong) Pharmaceutical synthesizes JAK2 inhibitors

Bexson expands ketamine patch pump program into depression

Discovery of novel APJ receptor agonist with promising activity in acute hemodynamic rat model

A-2342: a highly potent, selective, orally available NTCP inhibitor

Artizan and Biohaven begin therapeutic discovery and development program in Parkinson's

Researchers develop new model of heart failure with preserved ejection fraction

p21-controlled immunoclearance mechanism identified in senescent cells

Replication stress response defects signature predicts ICB response in nonhypermutated cancers

Study offers insights into post-MI fibrosis

Zika virus antagonism of mitophagy drives pathological proinflammatory chemokine expression

FAUST, a novel interpretable machine-learning method for unbiased discovery in single-cell cytometry

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...